Cytosurge AG

Cytosurge AG Driving the revolution. We provide scientists with FluidFM® to read and analyze life as it unfolds.

CellEDIT delivers vector-free, precise CRISPR engineering, even in hard-to-transfect cells.
👉 https://linktr.ee/cytosurge Cytosurge develops innovative research solutions using its proprietary FluidFM® technology for precise single-cell manipulation thereby fostering advancements in understanding cellular processes such as the ones that drive cancer. With the FluidFM OMNIUM platform, single-cell extracts, or “biopsies” can be taken from living cells, enabling live-sequencing and temporal transcriptomics analysis. Additionally, the CellEDIT Service provides high-quality genetically engineered cell lines through intra-nuclear injections of CRISPR RNPs. Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, enabling longer and healthier lives through precision gene engineering. The Company aims to implement advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and manufacturing, and empowering genetic engineers to realize their visionary concepts.

A decade of innovation, now in one definitive review. 🔬We are proud to share that a new Primer on "Fluidic Force Microsc...
19/02/2026

A decade of innovation, now in one definitive review. 🔬

We are proud to share that a new Primer on "Fluidic Force Microscopy" has been published in Nature Reviews Methods Primers.
Authored by the original pioneers, this review establishes as a transformative technology that has empowered ~140 labs worldwide with novel micro- and nanoscale capabilities.

From the Biology we champion at Cytosurge to additive manufacturing and beyond, FluidFM has opened entirely new research avenues.

What will FluidFM enable in the next decade?

• Read the Primer: https://bit.ly/4aJVuix
• And check out the , which highlights the different applications of FluidFM in biological and materials research: https://go.nature.com/46YA0gF

Competitors rejected these projects. We delivered.We recently achieved successful knockouts in a model, a notoriously ...
13/02/2026

Competitors rejected these projects. We delivered.
We recently achieved successful knockouts in a model, a notoriously difficult-to-transfect cell line, in a difficult-to-access genomic region.

Why did we succeed where others walked away?

bypasses the barriers with Direct, Vector-Free Delivery.
• Precise Stoichiometry: We control exactly how much RNP complex enters the cell.
• Gentle Handling: We keep fragile cells alive.

When standard methods fail, CellEDIT delivers.
"You name the edit, we edit it."

Today, on the International Day of Women and Girls in Science, the UN calls for "Inclusive Futures" to close the global ...
11/02/2026

Today, on the International Day of Women and Girls in Science, the UN calls for "Inclusive Futures" to close the global gender gap.
Cytosurge lives this vision: 50% Women. 50% Men. 100% Science & .
Together, we are driving the Same-Cell Revolution. Our FluidFM OMNIUM platform empowers scientists to tackle complex challenges and drive the next generation of breakthroughs.

To the women on our team and in labs worldwide: Thank you for redefining what’s possible.

Exciting news for the Greek life science community! 🔬We are proud to announce our partnership with N. Asteriadis S.A. fo...
27/01/2026

Exciting news for the Greek life science community! 🔬
We are proud to announce our partnership with N. Asteriadis S.A. for the distribution and support of the FluidFM OMNIUM system in Greece.
With roots dating back to 1955, N. Asteriadis S.A. is a true pillar of the Greek scientific community. Their decades of experience make them the ideal partner to provide not only the technology but also the expert local training and support you deserve.

We look forward to accelerating breakthroughs in Greek research together! 👉 https://asteriadis.gr/en/promitheutes/cytosurge/

22/01/2026

"We simply couldn't get the knockout to work in-house."😫
Sound familiar?

Dr. Alessandro Penna at the University of Padova was facing a common dilemma. His research on adoptive cell therapies for prostate cancer was stalled because a critical step - generating a PD-L1 knockout in PC-3 cells - proved impossible with standard methods.
Standard protocols failed. Troubleshooting was eating up valuable time.⏳

Instead of wasting more months optimizing reagents, he made a choice: Stop troubleshooting. Start researching. He turned to .

Using our direct nuclear injection technology, we bypassed the delivery limits of traditional methods and delivered a verified homozygous knockout, allowing his team to move immediately to validation experiments.✅

Don't let a difficult cell line hold back your breakthrough.
Read the full success story. Link in the first comment. 👇

What can you actually measure with Single-Cell Force Spectroscopy ( )?It is no longer just about "stickiness", mechanica...
20/01/2026

What can you actually measure with Single-Cell Force Spectroscopy ( )?
It is no longer just about "stickiness", mechanical force is a critical, functional biomarker for decoding cellular behavior. Using the OMNIUM platform, researchers are automating these measurements to drive breakthroughs in four distinct fields:
💊 Nanomedicine – Optimizing drug carrier retention. 🛡️ Immuno-Oncology – Quantifying T-cell killing efficiency. 🎗️ Cancer Mechanics – Predicting metastatic potential. 🦠 Microbiology – Deciphering infection mechanisms.

Want to see the data behind these applications? We have compiled recent case studies demonstrating exactly how these measurements are performed. 👉 Check them out on our blog: QR in the image below 👇, Links in the first comment 👇.

Studying the dormant stages of requires precision and flexibility. 🦟 You need to manipulate host cells and parasites w...
15/01/2026

Studying the dormant stages of requires precision and flexibility. 🦟 You need to manipulate host cells and parasites without constantly changing instruments or disrupting the sample.
That is exactly why Dr. Annemarie M. Voorberg-van der Wel and the team at the Biomedical Primate Research Centre ( ) chose our technology.

By consolidating critical workflows like microinjection and extraction onto a single system – the OMNIUM -, they can streamline their experiments and focus on their ultimate goal: finding a cure for relapsing malaria.
We are proud to support this critical work. 🚀

📖 Read the full story > Link in the first comment 👇

Large genomic deletions are often where standard CRISPR workflows hit a wall. Whether it is low cutting efficiency, repa...
13/01/2026

Large genomic deletions are often where standard CRISPR workflows hit a wall. Whether it is low cutting efficiency, repair artifacts, or the struggle to isolate the right clone, these projects frequently stall R&D timelines.💜
At CellEDIT, we don't just attempt the "hard" projects; we deliver them.
Recently, we successfully engineered a cell line with a complex >4kb deletion, delivering the verified clones to our client ahead of their timeline.

Our vector-free, intranuclear injection method allows us to bypass the limitations of traditional transfection methods and viral vectors, making "impossible" edits routine.

When your research requires complex genomic engineering, you need a partner who guarantees results, not just effort.💜

Have a complex editing project that others have turned down? Let's discuss feasibility. (Link below👇)

08/01/2026

A quick cut from our webinar with Dr. Ludovica Rizzo 💻 stop inferring fate from separate cell populations. Live seq follows the same cell across time points, building a longitudinal, causally linked dataset that drives decisions in R&D and bioprocessing. In other words, you get a linked longitudinal readout with causal information from a single experiment, turning insights directly into action for your model.

Watch the webinar recording 🎥 Check out the slides 👉
https://bit.ly/49tCsOz

New year, new energy, new goals - guided by the same vision. 🌍🧬As 2026 begins, we remain committed to redefining single-...
05/01/2026

New year, new energy, new goals - guided by the same vision. 🌍🧬
As 2026 begins, we remain committed to redefining single-cell analysis through dynamic, live-cell interaction. With the FluidFM OMNIUM platform and Live-seq, researchers can perform non-destructive cytoplasmic biopsies to link transcriptomes to phenotype in real time, opening new possibilities in cell fate tracking, mechanobiology, and beyond. 🔬✨
Thank you to our partners and the global scientific community for inspiring us to keep innovating.

🎯 What are your research goals for 2026? Whether it’s mastering a new workflow or solving a complex biological puzzle, we’d love to hear what drives you this year. Share your goals below! 👇

#2026

This year, focus on your science. Leave the engineering to us. ✨As we step into 2026, CellEDIT’s mission is clear: to br...
05/01/2026

This year, focus on your science. Leave the engineering to us. ✨

As we step into 2026, CellEDIT’s mission is clear: to bring your complex genetic ideas to life. Hard-to-transfect cells and challenging edits no longer slow therapeutic development.
Our vector-free, intra-nuclear injection workflow ensures precise, high-quality edits with minimal off-target effects. From design to ex*****on, we support every step, so you can focus on your research, while we make your edits happen.

Adresse

Sägereistrasse 25
Glattbrugg
8152

Öffnungszeiten

Montag 09:00 - 18:00
Dienstag 09:00 - 18:00
Mittwoch 09:00 - 18:00
Donnerstag 09:00 - 18:00
Freitag 09:00 - 18:00

Telefon

+41445331450

Webseite

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Cytosurge AG erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Verknüpfungen

Teilen

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Founded in 2009, Cytosurge AG successfully develops, manufactures and distributes cutting-edge and unique high-precision nanotechnology instruments as well as robotic systems based on its patented FluidFM® technology.

Whether via the FluidFM ADD-ON, a powerful upgrade solution for your AFM, the FluidFM BOT, a fully integrated system for cell research, or via the award-winning FluidFM µ3Dprinter for 3D metal printing at the micrometre scale, Cytosurge provides leading-edge tools and processes to those who need or want to go beyond current technological boundaries.

FluidFM – GO BEYOND.